Luigi Messori was born in Florence, on March 25, 1958.
He received his PhD in Chemical Sciences (1987) and became an Assistant Professor
(1990) and then Associate Professor (2004), in General and
Inorganic Chemistry. He is a member of the Department of
Chemistry, University of Florence. His main research interests
are in the fields of bioinorganic chemistry and metals
in medicine. In his initial work, he
studied the solution behavior of metalloproteins, mainly by
paramagnetic NMR, with emphasis on metal carrier proteins
(transferrins and metallothioneins) and on selected
zinc enzymes (carbonic anhydrase, carboxypeptidase).
Later on, starting from 1995, his research interests moved
to consider primarily the role of metal ions in medicine. In
particular, he directed his attention towards antitumor
metal-based drugs (mainly ruthenium and gold compounds) and their interactions with
nucleic acids and proteins. More recently, his studies exploited proteomics and metallomics
methods to disclose the molecular mechanisms of metal-based drugs at the
cellular level. He has been involved in various COST actions dealing with metal-based
drugs (D8, D20, D39, CM1105) with different roles. He has given several lectures in Italy
and abroad on the above topics. He is author of more than 300 papers, published in
international scientific journals.
Luigi Messori was born in Florence, on March 25, 1958.
He received his PhD in Chemical Sciences (1987) and became an Assistant Professor
(1990) and then Associate Professor (2004), in General and
Inorganic Chemistry. He is a member of the Department of
Chemistry, University of Florence. His main research interests
are in the fields of bioinorganic chemistry and metals
in medicine. In his initial work, he
studied the solution behavior of metalloproteins, mainly by
paramagnetic NMR, with emphasis on metal carrier proteins
(transferrins and metallothioneins) and on selected
zinc enzymes (carbonic anhydrase, carboxypeptidase).
Later on, starting from 1995, his research interests moved
to consider primarily the role of metal ions in medicine. In
particular, he directed his attention towards antitumor
metal-based drugs (mainly ruthenium and gold compounds) and their interactions with
nucleic acids and proteins. More recently, his studies exploited proteomics and metallomics
methods to disclose the molecular mechanisms of metal-based drugs at the
cellular level. He has been involved in various COST actions dealing with metal-based
drugs (D8, D20, D39, CM1105) with different roles. He has given several lectures in Italy
and abroad on the above topics. He is author of more than 300 papers, published in
international scientific journals.